Antengene Corp Ltd (6996)

Currency in HKD
5.10
+0.02(+0.39%)
Closed·
6996 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
6996 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.915.20
52 wk Range
0.535.92
Key Statistics
Bid/Ask
5.10 / 5.12
Prev. Close
5.08
Open
5.08
Day's Range
4.91-5.2
52 wk Range
0.53-5.92
Volume
2.3M
Average Volume (3m)
5.81M
1-Year Change
764.41%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
6996 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2.61
Downside
-48.90%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Antengene Corp Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Antengene Corp Ltd Company Profile

Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor for the treatment of cervical cancer and other advanced solid tumors. It also develops other clinical stage assets, such as ATG-022, an antibody-drug conjugate which is in Phase II for the treatment of patients with advanced or metastatic gastric cancer; ATG-031, an anti-CD24 monoclonal antibody, which is in Phase I for the treatment of advanced solid tumors; ATG-037, an CD73 inhibitor that is in Phase I for the treatment of locally advanced or metastatic solid tumors; and ATG-101, a PD-L1/4-1BB bispecific antibody, which is I Phase I trial for the treatment of advanced/metastatic solid tumors and B-cell non Hodgkin lymphoma (B-NHL). In addition, the company’s pre-clinical stage assets consist of ATG-042, an PRMT5-MTA inhibitor; ATG-201 a CD19 x CD3 T cell engager; ATG-102, a LILRB4 x CD3 T cell engager; ATG-106, a CDH6 x CD3 T cell engager; ATG-107, a FLT3 x CD3 T cell engager; and ATG-110, a LY6G6D x CD3 T cell engager. Further, the company develops AnTenGager, an 2+1 T cell engager platform which enables conditional T cell activation with reduced risk of cytokine release syndrome; and engages in the trading activities. Antengene Corporation Limited was founded in 2017 and is based in Shanghai, China.

Compare 6996 to Peers and Sector

Metrics to compare
6996
Peers
Sector
Relationship
P/E Ratio
−9.9x−13.2x−0.5x
PEG Ratio
−0.220.060.00
Price/Book
3.7x4.1x2.6x
Price / LTM Sales
34.5x4.2x3.3x
Upside (Analyst Target)
−48.9%−21.7%43.5%
Fair Value Upside
Unlock−10.2%6.8%Unlock

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 2.61
(-48.90% Downside)

Earnings

Latest Release
Apr 27, 2025
EPS / Forecast
-0.24 / --
Revenue / Forecast
31.17M / --
EPS Revisions
Last 90 days

6996 Income Statement

FAQ

What Stock Exchange Does Antengene Trade On?

Antengene is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for Antengene?

The stock symbol for Antengene is "6996."

What Is the Antengene Market Cap?

As of today, Antengene market cap is 3.47B.

What Is Antengene's Earnings Per Share (TTM)?

The Antengene EPS (TTM) is -0.51.

From a Technical Analysis Perspective, Is 6996 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Antengene Stock Split?

Antengene has split 0 times.

How Many Employees Does Antengene Have?

Antengene has 169 employees.

What is the current trading status of Antengene (6996)?

As of 09 Aug 2025, Antengene (6996) is trading at a price of 5.10, with a previous close of 5.08. The stock has fluctuated within a day range of 4.91 to 5.20, while its 52-week range spans from 0.53 to 5.92.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.